# MRTX849 acid

| | |
|---|---|
| **Cat. No.:** | HY-139402 |
| **CAS No.:** | 2561529-96-0 |
| **Molecular Formula:** | $C_{34}H_{37}ClFN_7O_4$ |
| **Molecular Weight:** | 662.15 |
| **Target:** | Ras |
| **Pathway:** | GPCR/G Protein; MAPK/ERK Pathway |
| **Storage:** | -20°C, protect from light, stored under nitrogen<br>* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 130 mg/mL (196.33 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 1.5102 mL | 7.5512 mL | 15.1023 mL |
| | 5 mM | 0.3020 mL | 1.5102 mL | 3.0205 mL |
| | 10 mM | 0.1510 mL | 0.7551 mL | 1.5102 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 3.25 mg/mL (4.91 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

MRTX849 acid, a derivative of MRTX849, can be used in the synthesis of PROTAC LC-2 (HY-137516). LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C ($DC_{50}$s between 0.25 and 0.76 μM)[1][2].

**$IC_{50}$ & Target**

KRas G12C

**In Vitro**

LC-2 induces degradation of endogenous KRASG12C in multiple KRAS mutant cancer cell (NCI-H2030, MIA PaCa-2, SW1573, NCI-H23 and NCI-H358 cells) with $DC_{50}$s between 0.25 and 0.76 μM. LC-2-induced KRASG12C degradation occurs via a bona fide PROTAC mechanism. MIA PaCa-2, NCI-H23, and SW1573 cells are treated with 2.5 μM of LC-2 for 6, 24, 48, and 72 h. In all three cell lines, maximal KRAS degradation occurred within 24 h and was sustained up to 72 h[1].

LC-2-induced (2.5 μM; 6-24 hours) KRAS G12C degradation modulates Erk signaling in homozygous and heterozygous KRAS mutant cell lines[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Bond MJ, et al. Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs. ACS Cent Sci. 2020;6(8):1367-1375.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA